Literature DB >> 28075618

Rodent models of glaucoma and their applicability for drug discovery.

Renu Agarwal1, Puneet Agarwal2.   

Abstract

INTRODUCTION: Rodents have widely been used to represent glaucomatous changes both in the presence and absence of elevated intraocular pressure (IOP) as they offer clear advantages over other animal species. IOP elevation is commonly achieved by creating an obstruction in the aqueous outflow pathways, consequently leading to retinal ganglion cell and optic nerve (ON) damage, the hallmark of glaucoma. These changes may also be achieved in the absence of elevated IOP by directly inflicting injury to retina or ON. Areas covered: This paper presents a summary of currently used rodent models of glaucoma. The characteristics of these models from several studies are summarized. The benefits and shortcomings of these models are also discussed. Expert opinion: The choice of animal model that closely represents human disease is key for successful translational of preclinical research to clinical practice. Rodent models of rapid IOP elevation are likely to be least representative, whereas models such as steroid-induced glaucoma models more closely resemble the trabecular meshwork changes seen in glaucomatous human eyes. However, this model needs further characterization. Rodent models based on direct retinal and ON injury are also useful tools to investigate molecular mechanisms involved at the site of final common pathology and neuroprotective strategies.

Entities:  

Keywords:  Glaucoma models; intraocular pressure; optic nerve; retinal ganglion cells; rodents

Mesh:

Substances:

Year:  2017        PMID: 28075618     DOI: 10.1080/17460441.2017.1281244

Source DB:  PubMed          Journal:  Expert Opin Drug Discov        ISSN: 1746-0441            Impact factor:   6.098


  7 in total

1.  Laser Capture Microdissection of Highly Pure Trabecular Meshwork from Mouse Eyes for Gene Expression Analysis.

Authors:  Caleb Sutherland; Yu Wang; Robert V Brown; Julie Foley; Beth Mahler; Kyathanahalli S Janardhan; Ramesh C Kovi; Anton M Jetten
Journal:  J Vis Exp       Date:  2018-06-03       Impact factor: 1.355

2.  Interleukin-4 promotes microglial polarization toward a neuroprotective phenotype after retinal ischemia/reperfusion injury.

Authors:  Di Chen; Cheng Peng; Xu-Ming Ding; Yue Wu; Chang-Juan Zeng; Li Xu; Wen-Yi Guo
Journal:  Neural Regen Res       Date:  2022-12       Impact factor: 6.058

3.  Taurine protects against retinal and optic nerve damage induced by endothelin-1 in rats via antioxidant effects.

Authors:  Natasha Najwa Nor Arfuzir; Renu Agarwal; Igor Iezhitsa; Puneet Agarwal; Sabrilhakim Sidek; Nafeeza Mohd Ismail
Journal:  Neural Regen Res       Date:  2018-11       Impact factor: 5.135

4.  Protective effect of magnesium acetyltaurate and taurine against NMDA-induced retinal damage involves reduced nitrosative stress.

Authors:  Azliana Jusnida Ahmad Jafri; Renu Agarwal; Igor Iezhitsa; Puneet Agarwal; Alexander Spasov; Alexander Ozerov; Nafeeza Mohd Ismail
Journal:  Mol Vis       Date:  2018-07-25       Impact factor: 2.367

5.  A Robust Microbead Occlusion Model of Glaucoma for the Common Marmoset.

Authors:  Sandeep Kumar; Alexandra Benavente-Perez; Reynolds Ablordeppey; Carol Lin; Suresh Viswanathan; Abram Akopian; Stewart A Bloomfield
Journal:  Transl Vis Sci Technol       Date:  2022-01-03       Impact factor: 3.283

6.  Long-term corticosteroid-induced chronic glaucoma model produced by intracameral injection of dexamethasone-loaded PLGA microspheres.

Authors:  M J Rodrigo; D Garcia-Herranz; A Aragón-Navas; M Subias; T Martinez-Rincón; S Mendez-Martínez; M J Cardiel; J García-Feijoo; J Ruberte; R Herrero-Vanrell; L Pablo; E Garcia-Martin; I Bravo-Osuna
Journal:  Drug Deliv       Date:  2021-12       Impact factor: 6.819

7.  Mimicking chronic glaucoma over 6 months with a single intracameral injection of dexamethasone/fibronectin-loaded PLGA microspheres.

Authors:  Alba Aragón-Navas; María J Rodrigo; David Garcia-Herranz; Teresa Martinez; Manuel Subias; Silvia Mendez; Jesús Ruberte; Judit Pampalona; Irene Bravo-Osuna; Julian Garcia-Feijoo; Luis E Pablo; Elena Garcia-Martin; Rocío Herrero-Vanrell
Journal:  Drug Deliv       Date:  2022-12       Impact factor: 6.819

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.